Ardent Health Partners Inc. logo

Ardent Health Partners Inc. (ARDT)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
11. 95
-0.25
-2.0492%
$
1.62B Market Cap
- P/E Ratio
- Div Yield
660,100 Volume
- Eps
$ 12.2
Previous Close
Add Transaction
Day Range
11.95 12.46
Year Range
7.71 15.48
Want to track ARDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript

Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript

Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript

Seekingalpha | 7 months ago
Ardent Health, Inc. (ARDT) Lags Q4 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) Lags Q4 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.81 per share a year ago.

Zacks | 7 months ago
This Stock Is Pumping Huge Cash For Its Price

This Stock Is Pumping Huge Cash For Its Price

We believe Ardent Health (ARDT) stock is worth considering: It is growing, generating cash, and is priced at a notable valuation discount. Companies of this caliber can utilize cash to drive further revenue growth, or simply reward their shareholders through dividends or buybacks.

Forbes | 9 months ago
Could Ardent Health Be A Value Buy Right Now?

Could Ardent Health Be A Value Buy Right Now?

We believe Ardent Health (ARDT) stock deserves attention: It is growing, generating cash, and is priced significantly below its valuation. Companies like this can utilize cash to drive further revenue growth or distribute it to their shareholders via dividends or buybacks.

Forbes | 9 months ago
New Strong Sell Stocks for Nov. 18th

New Strong Sell Stocks for Nov. 18th

DIOD, ARDT and FFIV have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2025.

Zacks | 11 months ago
Ardent Health, Inc. (ARDT) Q3 2025 Earnings Call Transcript

Ardent Health, Inc. (ARDT) Q3 2025 Earnings Call Transcript

Ardent Health, Inc. ( ARDT ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants David Styblo - Senior Vice President of Investor Relations Martin Bonick - President, CEO & Director Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Jason Cassorla - Guggenheim Securities, LLC, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Zach Haggerty Raj Kumar - Stephens Inc., Research Division Craig Hettenbach - Morgan Stanley, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.

Seekingalpha | 11 months ago
Ardent Health, Inc. (ARDT) Surpasses Q3 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) Surpasses Q3 Earnings and Revenue Estimates

Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.19 per share a year ago.

Zacks | 11 months ago
Ardent Health, Inc. (ARDT) Q2 Earnings and Revenues Surpass Estimates

Ardent Health, Inc. (ARDT) Q2 Earnings and Revenues Surpass Estimates

Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.35 per share a year ago.

Zacks | 1 year ago
Analysts Estimate Ardent Health, Inc. (ARDT) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Ardent Health, Inc. (ARDT) to Report a Decline in Earnings: What to Look Out for

Ardent Health, Inc. (ARDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Ardent Health: The Best Prospect In An Industry That's Facing Challenges

Ardent Health: The Best Prospect In An Industry That's Facing Challenges

Ardent Health faces significant legislative risks, due to Medicaid and Medicare cuts, causing uncertainty and a recent downgrade, but much of this is priced in. Despite headwinds, Ardent Health demonstrates strong revenue and profitability growth, low leverage, and trades at compellingly cheap valuations, versus peers. Management projects continued growth for 2025, with revenue and EBITDA expected to rise, supported by higher-margin service expansions and acquisitions.

Seekingalpha | 1 year ago
Wall Street Analysts Predict a 36.55% Upside in Ardent Health Partners, Inc. (ARDT): Here's What You Should Know

Wall Street Analysts Predict a 36.55% Upside in Ardent Health Partners, Inc. (ARDT): Here's What You Should Know

The mean of analysts' price targets for Ardent Health Partners, Inc. (ARDT) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 1 year ago
Ardent Health Partners, Inc. (ARDT) Q1 2025 Earnings Call Transcript

Ardent Health Partners, Inc. (ARDT) Q1 2025 Earnings Call Transcript

Ardent Health Partners, Inc. (NYSE:ARDT ) Q1 2025 Earnings Conference Call May 7, 2025 10:00 AM ET Company Participants David Styblo - Senior Vice President of Investor Relations Marty Bonick - President and Chief Executive Officer Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Whit Mayo - Leerink Partners Ann Hynes - Mizuho Craig Hettenbach - Morgan Stanley Ben Hendrix - RBC Capital Markets Joanna Gajuk - Bank of America Matthew Gillmor - KeyBanc Benjamin Rossi - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Ardent Health Partners First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.

Seekingalpha | 1 year ago
Loading...
Load More